Dr. Phuphanich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11949 Jefferson Blvd. Ste 102
Los Angeles, CA 90230Phone+1 424-257-8869Fax+1 310-602-6446
Summary
- My main clinical and research interests are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new targeted therapeutic agents i.e. M-Tor inhibitor, EGFR-TKI, VEGFR, Monoclonal antibody, Gene therapy and Immunotherapy with Vaccine and Stem cell for different specific cancer cell targets including correlation with proteinomic, genomic profile in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized Neuro-Oncology medicine for every patient with brain cancer. I have more than 25 years of experience in this field for translational clinical research.
Education & Training
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1978 - 1979
- Ascension Illinois/Saint FrancisInternship, Internal Medicine, 1977 - 1978
- Mahidol University Faculty of MedicineClass of 1975
- Mahidol UniversityB.S., Faculty of Science, 1973
Certifications & Licensure
- CA State Medical License 2006 - 2026
- OR State Medical License 2022 - 2025
- AZ State Medical License 2016 - 2021
- FL State Medical License 1983 - 2009
- GA State Medical License 2003 - 2009
- IL State Medical License 1978 - 1984
- American Board of Psychiatry and Neurology Neurology
- United States Department of Justice Drug Enforcement Administration (DEA)
Awards, Honors, & Recognition
- LA’s Top Doctors, Los Angeles Magazine Los Angeles Magazine, 2021
- Top Doctors:LA Area Castle Connolly, 2013, 2016
- Top's American Doctors for Cancer Castle Connelly Medical Ltd, 2006-2016
- Join now to see all
Clinical Trials
- Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma Start of enrollment: 2002 Jun 01
- Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas Start of enrollment: 2004 Mar 01
- Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 273 citationsRandomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous MeningitisMichael Glantz, Suzanne LaFollette, Kurt A. Jaeckle, William R. Shapiro, Lode J. Swinnen
Journal of Clinical Oncology. 1999-10-01 - 147 citationsA Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert Aiken
Clinical Cancer Research. 2019-10-01 - 801 citationsEffect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical TrialDavid A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim
JAMA Oncology. 2020-07-01
Journal Articles
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaDavid A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
- A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation ...Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli VK, LoghinM, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I..., J Neurooncol, 1/1/2015
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaNorden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ..., Neurology, 1/1/2015
- Join now to see all
Abstracts/Posters
- Nanoconjugates for inhibition of laminin 411-integrin B1 Dll4 Notch1 pathway to treat glioblastoma multiformeGangalum PR, Ljubimov AV, Chesnokova A, Konda B, Ding H, Portilla-Arias J, Mamelak A, Bannykh S, Rudnick J, Hu J, Black KL, Ljubimova JY, Cancer Res, 1/1/2014
- A randomized, double blind, controlled phase II trial of dendritic cell (DC) vaccination with ICT107 in newly diagnosed glioblastoma (GBM) patientsWen P, Reardon D, Armstrong T, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peerboom D, Markert J, Grewal J, LaRocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G..., American Society of Clinical Oncology, Chicago, IL, 1/1/2014
- BTTC08 01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT prom...Raizer J, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli V, Loghin M, Paleologos N., Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-L..., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
- Join now to see all
Lectures
- Advances in Neuro-Oncology 2015: Biomarker, Liquid Biopsy Immuno-Oncology, NovoTTFRamathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/16/2015
- Targeted Therapy for Brain Cancer: Early Detection and New BiomarkerMahachai Hospital Group, Samutsakhon, Thailand - 1/15/2015
- Immunotherapy for Brain cancer: Vaccine, ICT 107 Anti PD1 PD L1 AntibodyHouston Methodist Hospital, Houston, TX - 1/24/2014
- Join now to see all
Authored Content
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Press Mentions
- Update: 50 Percent of Patients in New Brain Cancer Study Alive After Five YearsNovember 24th, 2013
- Vaccine Targets Malignant Brain Cancer Antigens, Significantly Lengthens SurvivalAugust 15th, 2012
- Vaccine Study Supports Immune Targeting of Brain TumorsJune 17th, 2011
Professional Memberships
- Fellow
- Member
- Society for Neuro-Oncology (SNO)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: